We examined the kinetics of Gα s and Gα i regulation of human type V and type VI adenylyl cyclase (AC V and AC VI) in order to better model interactions between AC and its regulators. Activation of AC VI by Gα s displayed classical Michaelis-Menten kinetics, whereas AC V activation by Gα s was cooperative with a Hill coefficient of 1.4. The basal activity of human AC V, but not that of AC VI, was inhibited by Gα i . Both enzymes showed greater inhibition by Gα i at low Gα s concentrations, however, human AC V was activated by Gα i at high Gα s concentrations. Neither regulator had an effect on the K m for Mg-ATP. Mutations made within the Gα s binding pocket of AC V (N1090D) and VI (F1078S) displayed 6-fold and 14-fold greater EC 50 's for Gα s activation but had no effect on Gα i inhibition of basal activity or K m for Mg-ATP. Gα s -stimulated AC VI-F1078S was not significantly inhibited by Gα i , despite normal inhibition by Gα i upon forskolin-stimulation. Mechanistic models for Gα s and Gα i regulation of AC V and VI were derived to describe these results. Our models are consistent with previous studies, predicting a decrease in affinity of Gα i in the presence of Gα s . For AC VI, Gα s is required for inhibition, but not binding by Gα i . For AC V, binding of two molecules of Gα s and Gα i to an AC dimer are required to fully describe the data. These models highlight the differences between AC V and VI and the complex interactions with two important regulators.
INTRODUCTION
The key to regulation of adenylyl cyclase (AC) activity is the conformational state of the enzyme at the interface of the two large cytoplasmic domains (1) (2) (3) . Gα s binds to the second cytoplasmic (C 2 ) domain of AC and increases the affinity of the two domains for one another to promote catalysis (4) (5) (6) (7) (8) . Gα i works in direct opposition to Gα s , binding to the first cytoplasmic domain (C 1 ) and decreasing domain interaction to reduce formation of the AC catalytic site (3, 9) .
Although conformational changes at the domain interface are critical for regulation, other regions of AC play important roles as well. For example, the N-terminus of rat AC VI interacts with the C 1 domain to modulate Gα i -mediated inhibition (10) and glycosylation of AC VI may alter regulatory properties of the enzyme (11) . Although native and recombinant Gα s have similar effects on the cytoplasmic domains of AC, activation of full-length AC is less effectively inhibited by Gα i upon stimulation of native versus recombinant Gα s (12) . Kleuss and Krause speculate that the palmitate on native Gα s competes with the myristate on Gα i for a hydrophobic binding pocket on AC (12) . Previous studies by Taussig et al. (13) suggest that both Gα s and Gα i are bound simultaneously to the enzyme, seemingly in contradiction to studies using the independently expressed cytoplasmic domains (3) . In an attempt to fully understand the regulation of full-length human AC V and VI, we have modeled the kinetics of Gα s /Gα i regulation.
Types V and VI AC are generally grouped together as being highly related AC isoforms.
They are both activated by Gα s and forskolin and are inhibited by Gα i , free calcium, and RGS2 (14) (15) (16) (17) (18) (19) (20) . However, several differences may exist. AC V is activated by protein kinase C (PKC) alpha and zeta (21) , whereas, AC VI is inhibited by PKC delta and epsilon (22) . These enzymes are also different in how they respond to regulation by Gα s and Gα i . We show herein, that the basal activity of human AC V, but not that of AC VI, is inhibited by Gα i . Both enzymes show greater inhibition by Gα i at low Gα s concentrations, however, Gα i activates human AC V at high Gα s concentrations. Mutations within the Gα s binding pocket of AC V and VI also reveal differences in the regulatory pattern of these enzymes. Models will be presented that highlight these differences and describe the kinetics of these two important regulators.
MATERIALS AND METHODS

Plasmid Construction and Generation of Recombinant Baculovirus. A 4.1 kb fragment
containing the entire coding sequence of human type VI AC was transferred from hAC6-pCDNA to the baculovirus expression vector pfastbacdual using the restriction enzymes EcoRI and NotI.
Human AC V was constructed by ligation of a 3.8 kb HindIII fragment from hAC5-pCDNA to HindIII-digested pfastbacdual.
The human adenylyl cyclase type VI mutant, F1078S, was constructed using the PCR overlap extension method (23) . Primers flanking each side of the desired mutation were used starting at position 2687 of the coding strand (2687C) and 3552 of the reverse strand (3552R).
The nucleotide sequences of the mutagenic primers (F1078S-R and F1078S-F) were selected by replacement of the wild type phenylalanine codon with the codon for serine. The 2687C/F1078SR and 3552R/F1078SF fragments were generated with a standard PCR reaction mixture using pfu polymerase (Stratagene). The fragments were purified from a 1% agarose gel and used in a second PCR reaction to make the complete 2687C/3552R mutant fragment. The fragment was cloned into pfastbacdual-hACVI using restriction enzymes SalI and BstEII. The human AC V mutants, N1090D and V476A, were created using the same method and were cloned into pfastbacdual-hACV using the restriction enzymes AgeI and EcoNI (for N1090D) and BamHI and AatII (for V476A). The desired clones were verified by DNA sequencing.
Generation of recombinant baculoviruses was performed according to the manufacture's specifications (Invitrogen). A baculovirus containing the pfastbacdual vector alone was also generated for background subtraction of activities.
Membrane Preparation. Sf9 cell membranes containing desired adenylyl cyclase isoforms and mutants have been prepared according to procedures described previously (24).
Purification and Activation of G Protein Subunits. Gα s was expressed and purified from the E. coli strain, BL21(DE3), as described by Lee et al (25) . Myristoylated Gα i1 protein was produced by co-expression of Gα i with yeast protein N-myristoyltransferase as described previously (25, 26) . Purified α-subunits were activated by incubation with 50 mM NaHEPES (pH Adenylyl Cyclase Assays. Activity of adenylyl cyclase was determined as described (27) .
All assays were performed for 8-11 min at 30 °C in a final volume of 50µl. The final concentration of MgCl 2 and Mg-ATP in the assay mixture was 5 mM and 250 µM. Membranebound adenylyl cyclases were incubated with G protein subunits for 20 min on ice prior to initiation of the reaction. Under these conditions, protein activity remained linear for greater than 15 min at 30 °C over a large range of membrane concentrations. To determine the K m for substrate, the concentration of Mg-ATP was varied from 10 µM to 320 µM. The consumption of ATP was less than 10% of total. All determinations were performed in duplicate or triplicate and experiments shown were repeated at least twice. The endogenous Sf9 AC activity was subtracted from all measurements of basal activity and for Gα s activation curves for AC VI. The activity of vector-alone infected Sf9 cell membranes represented between 10-30% of the total activity under all conditions for AC VI and 3-15% for AC V; the highest contribution from endogenous activity occurring under basal conditions. Overall analysis of activity remained essentially the same with or without background subtraction.
Steady-State Kinetic Model. The rate equations for the reaction schemes presented in (AC-Gs 2 ), v6 (AC-Gs 2 -Gi), and v7 (AC-Gs 2 -Gi 2 ). Endogenous Sf9 activity was subtracted at all Gα i concentrations of basal activity.
RESULTS AND DISCUSSION
Gα s Activation of AC --Gα s strongly activates all isoforms of mammalian membranebound ACs. Human AC V and AC VI were stimulated 250-fold and almost 500-fold by Gα s , respectively (Fig. 1A,B) . increases; from a robust 82% inhibition of activity at 10-50 nM Gα s (representing 1.8 -18% of full activity by Gα s ) to a modest 25% inhibition upon full activation by Gα s ( Fig. 2A, B ). This has been previously observed with the canine AC V enzyme (13) . The low concentrations of Gα s giving rise to the greatest inhibition by Gα i , are also those concentrations that show the most positive cooperativity and deviation from Michaelis-Menten kinetics.
Human AC V showed a similar trend as AC VI with respect to Gα i inhibition, but with a surprising twist. Low concentrations of Gα s supported a strong 70% inhibition by Gα i , whereas higher concentrations of Gα s led to activation by Gα i ( Fig (Tables I and II which is located in the loop between the α1 and α2 helices in C 2 was mutated to aspartate in AC V (29) . Previous studies showed that mutation of these residues greatly reduced Gα s affinity but had little effect on the overall V max or activation by forskolin when mutated in canine type V AC or in type II AC (7, 8) . The mutation of F1078 in human AC VI to serine showed similar levels of overall activity when stimulated maximally with forskolin and Gα s (Fig. 3A) with only a 2-4 fold increase in K m for Mg-ATP (Table I) . N1090D-AC V showed a reduction in overall activity ( Fig. 3D ) but no change in the K m for Mg-ATP (Table II) . As predicted, F1078S-AC VI and N1090D-AC V had greatly reduced Gα s activity as compared to wild-type (Fig 3A, D) , displaying a 14-fold and 6-fold decrease, respectively, in the EC 50 for Gα s activity (Fig. 3B, E) .
Gα i Inhibition of AC VI-F1078S
--Gα i did not inhibit the basal activity of the mutant F1078S, similar to wild-type AC VI (Fig. 3C ). Gα i also failed to significantly inhibit Gα sstimulated activity of the mutant F1078S (Fig. 4A, B ). This might have been expected for extremely low levels of Gα s , where activation was not greatly above basal activity. However, stimulation with 1 and 3 µM Gα s produced activity that was 8 and 13 fold above basal activity and represented an estimated 30-40% of total activity. For the wild-type enzyme, this level of activation displayed the greatest inhibition by Gα i (75-80%), whereas the mutant F1078S displayed a maximum of 20-25% inhibition by Gα i at the highest concentrations of Gα s tested and only 10-15% inhibition at lower concentrations of Gα i .
The lack of Gα i inhibition was not due to an inability of the mutant enzyme to bind or respond to Gα i . Upon stimulation with forskolin, the mutant was inhibited to an even greater degree than the wild-type enzyme, despite having a 3 fold lower EC 50 for forskolin and increased activity (Fig. 5A, B) . Unlike for Gα s stimulation, inhibition of forskolin-stimulated AC VI did not appear to be dependent on the degree of activation. Activation by low and moderate concentrations of forskolin produced nearly identical Gα i inhibition curves. Second this model requires Gα s for inhibition, but not binding, by Gα i . This prediction is supported by the F1078S mutation of the Gα s binding site, which not only reduces the affinity of Gα s , but also largely prevents the conformational change necessary for Gα i inhibition. In addition, Gα i binds to the isolated C 1 domain of AC VI (data not shown) suggesting that it could also bind the full-length enzyme. Finally, we were unable to fit our experimental data to models that do not allow for Gα i binding to the basal state of AC VI. If Gα i is not allowed to bind to AC VI alone, maximum inhibition occurs at high, not low levels of Gα s . This is due to the fact that our model predicts only a ~20% inhibition of the ACVI-Gα s complex by Gα i ; the high degree of inhibition by Gα i at low concentrations of Gα s is obtained from the formation of the AC VI-Gα i complex in the wake of reduced Gα s affinity (Fig. 6) .
Modeling of Human AC V --In formulating our model for AC VI, we chose to ignore the small deviation from Michaelis-Menten kinetics for Gα s activation of AC VI. This was largely due to the high quality of the fits to experimental data using the model as presented. Other models tested did not significantly aid our data analysis. Thus, if synergistic Gα s activation is indicative of multimerization of AC as some evidence suggests (30,32), it does not significantly alter the kinetics of Gα i regulation for AC VI.
However, for AC V we simply could not ignore the cooperative activation by Gα s . In light of the crystal structure and a significant amount of biochemical data, we find it unlikely that 2 Gα s sites are present on a single AC monomer (6) (7) (8) 29) . If true, mutagenesis of one site should leave a second site intact. However, mutations within the "known" Gα s -binding site do not support this conclusion; particularly mutations made within a soluble C 1 -C 2 construct which show the same phenotype as those made within the membrane-bound AC. More likely AC V, and possibly AC VI, is capable of forming dimers or multimers. Complementation of mutant AC I molecules, non-Michaelis-Menton Gα s activation curves, and more recently clever FRETbased strategies using AC 8, have pointed to the existence of AC dimers/multimers (30, 32, 33) .
Thus in our model we assumed that AC V represented at least a dimer and that 2 Gα s molecules could simultaneously bind this dimeric/multimeric AC V giving rise to an AC x -Gs 2 complex.
However models that did not allow for Gα i binding to AC x -Gs 2 , accurately predicted Gα s cooperative activation, but failed to predict the inhibition, followed by activation by Gα i at moderate Gα s concentrations. The same was true for models that did not allow for Gα i binding
to AC x -Gs 2 -Gi. The only model with the least number of parameters that accurately fit the data presented is shown in Fig. 7A . The main features of this model are the requirement for multiple The major difference between canine and human AC V and between human AC V and human AC VI lies in the N-terminus. Human, rat, and rabbit AC V share similar N-termini, however, canine share almost no homology in this region due to differential splicing (34) . The N-terminus of human AC V also shares almost no homology with that of AC VI. Deletion of the N-terminus in AC VI does not alter the regulation by Gα s or forskolin or the sensitivity to P-site inhibitors (10) . The N-terminus of AC VI is the site of PKC inhibition of AC VI (22, 35) and it has been suggested that the N-terminus modulates Gα i -mediated inhibition of AC VI via binding to the C 1a domain (10) . It is possible that the N-terminus of AC V also plays a role in the regulation of activity and thus may provide the key to species differences for AC V and the differences in regulation of basal and Gα s -stimulated activities for human AC V and VI. The other major difference between isoforms lies in the membrane spanning regions. For AC 8, the membrane spans were the major determinant for interactions between AC molecules (32) and thus may give rise to the cooperative activation by Gα s . Thus, the N-terminus and membranespanning regions may provide the fine-tuned regulatory differences observed between AC isoforms.
In conclusion, we have described models for Gα s and Gα i regulation of human AC V and AC VI. Our studies have highlighted the differences between the mechanisms of activation and inhibition for these closely related AC isoforms and provide additional evidence for the need for higher order complexes of AC to fully explain the complexity of AC activation and inhibition. Determinations were performed in triplicate. [ 
